Most people asking about psychedelics and their prescriptions want to know one thing: which combinations worry researchers? This page lists them, from the clearest warning signs to the thinnest evidence, and says how strong each finding is. The evidence differs by combination, and a 2022 review found far more research on MDMA than on psilocybin [3].
If you take an SSRI or SNRI antidepressant, our page on psilocybin and SSRIs covers that combination in detail.
The short version
- Lithium: online reports and a published case describe seizures after lithium was combined with classic psychedelics such as psilocybin or LSD [4] [6].
- MAOIs, an older class of antidepressant, including MAO-inhibiting compounds found in ayahuasca: reviews describe potentially fatal interactions with MDMA and amphetamines, and warn about serotonin toxicity with medicines that raise serotonin [8] [10] [11].
- Tricyclic antidepressants and lithium taken for three weeks or more may strengthen psychedelic effects, according to FDA guidance for researchers [1].
- SSRIs, SNRIs and MAOIs taken for three weeks or more may weaken them [1].
- Some antipsychotics reduced psilocybin's effects in studies, while haloperidol increased anxiety [2] [13].
- Ibogaine can cause dangerous heart rhythm problems, and other medicines can add to that risk [14] [15].
- Never stop or change a medication on your own. Talk with your prescriber.
What the FDA tells researchers
In July 2026 the FDA finalized guidance for companies running psychedelic drug trials. It is guidance for researchers, not a drug label. On other medicines, it says [1]:
- Taking a tricyclic antidepressant or lithium for three weeks or more may strengthen the effects people feel, which the FDA calls a potential psychiatric safety concern.
- Taking an SSRI, SNRI or MAOI for three weeks or more may reduce the effects, and taking one for less than three weeks may strengthen them.
- An MAOI combined with MDMA or other amphetamine-based psychedelics "can produce a life-threatening hypertensive crisis," a sudden, dangerous rise in blood pressure.
Lithium
An analysis of unverified online reports found a seizure signal when lithium was combined with a classic psychedelic, and none with lamotrigine, another mood stabilizer. The authors provisionally conclude that psychedelic use may pose a significant seizure risk for people on lithium [4]. Our psilocybin and SSRIs page gives the figures.
A 2024 case report describes seizures in a 15-year-old who used LSD soon after starting low-dose lithium, while also taking fluoxetine and bupropion. The authors could not prove a cause, and say the case suggests an increased risk [6]. A 1996 questionnaire study found that people taking lithium long-term reported stronger responses to LSD [7]. A 2024 review concluded that psychedelics alone may not raise seizure risk in healthy people, while combining them with drugs such as lithium could [5].
MAOIs, including ayahuasca
Monoamine oxidase inhibitors (MAOIs) are older antidepressants such as phenelzine and tranylcypromine. The plant brew ayahuasca also contains MAO-inhibiting compounds [11].
Blood pressure. A 2026 review of 219 publications found reports of dangerous blood pressure spikes when MAOIs were combined with amphetamines, cocaine, methamphetamine and psilocybin mushrooms, among other substances [8]. One of those reports is a 2024 case involving mushrooms, an MAOI and an amphetamine, written partly by the same authors. They suspected compounds in the mushrooms and the amphetamine rather than psilocybin itself, and advise that people prescribed MAOIs be warned about this risk [9].
Serotonin toxicity. This is a reaction to too much serotonin activity, and serotonin syndrome is its most severe form. A 2022 review found that it typically happens with an overdose, or when a drug that raises serotonin is combined with an MAOI. It rated serotonergic medicines without MAOIs as low risk when combined with psychedelics that also contain none [10]. In 1998, researchers warned that ayahuasca combined with SSRI antidepressants may cause serotonin syndrome with a potentially grave outcome [11].
Deaths and weaker effects. The 2026 review reports deaths when MAOIs were combined with MDMA, 5-MeO-DMT or amphetamines. It concludes that MDMA and amphetamines can pose potentially fatal risks with MAOIs [8]. Long-term MAOI use may weaken the effects of LSD [7]. In a small 1968 study, two days of an MAOI did not significantly reduce psilocybin's effects, but it did push blood pressure higher [12].
Tricyclic antidepressants
In the 1996 questionnaire study, people taking a tricyclic antidepressant long-term reported stronger physical, visual and psychological responses to LSD [7]. The FDA's 2026 guidance treats this as a potential psychiatric safety concern [1].
Antipsychotics and benzodiazepines
In a 1998 study in healthy volunteers, the antipsychotic risperidone and the research drug ketanserin blocked psilocybin's effects [13]. The older antipsychotic haloperidol reduced some effects but increased anxiety [2]. A 2022 review found no studies of benzodiazepines, a class of anti-anxiety medicine, taken with psilocybin or MDMA [3].
MDMA, LSD and other medicines
Some antidepressants slow CYP2D6, a liver enzyme that breaks down several psychedelics. In trials reviewed in 2022, fluoxetine and paroxetine raised MDMA levels in the blood even though they weakened MDMA's effects, and bupropion raised MDMA levels and prolonged its mood effects. Bupropion and MDMA can both lower the seizure threshold [3]. In a 2025 trial, paroxetine raised LSD levels in the blood [16].
Ibogaine
Ibogaine is an unlicensed plant compound that some people use to treat addiction. It can lengthen the heart's QT interval, which can lead to dangerous heart rhythms and sudden cardiac arrest, and deaths have been reported [14]. A 2026 review says these events happen even in people without known heart conditions [15]. Because CYP2D6 breaks down ibogaine, other medicines can interact with it, and a 2016 review expects more deaths, particularly in people with heart conditions or taking other medicines [14].
What the research does not show
- It does not show any combination is safe. Most of the evidence is case reports, self-reports and small studies [2] [3] [12].
- It covers few medicines. The research on interactions is limited, and only a small number of medicines have been studied [2] [3].
When to get help
Call 911 for a seizure, muscle jerking, high fever, severe muscle stiffness, chest pain, a severe headache with very high blood pressure, or agitation with a racing heart [9] [10].
Talk with your prescriber or pharmacist before any change to a medication, and tell them honestly what you are considering. After a hard experience, see After a difficult psychedelic experience.
Common questions
Can I take psilocybin on lithium?
The authors of an analysis of online reports provisionally concluded that psychedelic use may pose a significant seizure risk for people taking lithium [4]. FDA guidance for researchers also flags lithium [1]. Do not stop lithium on your own. Talk with your prescriber.
Is ayahuasca safe with antidepressants?
Ayahuasca contains MAO inhibitors. Researchers have warned since 1998 that combining it with SSRI antidepressants may cause serotonin syndrome [11], and a 2024 review advises caution with SSRIs and SNRIs [2].
What about my ADHD medicine?
In a controlled study, methylphenidate taken with MDMA increased unpleasant effects, and the researchers concluded the combination would add to heart and blood pressure effects [3]. The 2024 blood pressure emergency involved an amphetamine, an MAOI and mushrooms [9]. These findings do not cover every ADHD medicine with every psychedelic. Ask your prescriber.
Sources (16)
- Psychedelic Drugs: Considerations for Clinical Investigations. U.S. Food and Drug Administration, 2026.
- Drug-drug interactions involving classic psychedelics: A systematic review. Journal of Psychopharmacology, 2024.
- Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology, 2022.
- Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. Pharmacopsychiatry, 2021.
- Do classic psychedelics increase the risk of seizures? A scoping review. European Neuropsychopharmacology, 2024.
- New-Onset Seizures in an Adolescent Following Use of LSD while on Low-Dose Lithium Therapy: A Case Study. South Dakota Medicine, 2024.
- Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behavioural Brain Research, 1996.
- Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data. CNS Drugs, 2026.
- Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine. Journal of Psychoactive Drugs, 2024.
- Serotonin toxicity of serotonergic psychedelics. Psychopharmacology, 2022.
- Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. Journal of Psychoactive Drugs, 1998.
- Concomitant use of antidepressants and classic psychedelics: A scoping review. Journal of Psychopharmacology, 2025.
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport, 1998.
- How toxic is ibogaine?. Clinical Toxicology, 2016.
- Rare but relevant: Ibogaine and cardiovascular complications, prolonged QT interval and ventricular arrhythmias. Addiction, 2026.
- Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial. Clinical Pharmacology and Therapeutics, 2025.